ESC Premium Access

Differences in the characteristics of patients with non-valvular atrial fibrillation who are newly prescribed apixaban, rivaroxaban, dabigatran and VKA in general practice in the UK

Congress Presentation

About the speaker

Ms Gillian Stynes

Uxbridge (United Kingdom of Great Britain & Northern Ireland)
0 follower

20 more presentations in this session

Prothrombin activation fragment (F1+2) as an index of anticoagulant therapy with factor Xa inhibitor in atrial fibrillation

Speaker: Doctor E. Ueno (Kahoku, JP)


Is there a difference in treatment persistence across oral anticoagulants? Results of a UK cohort study evaluating oral anticoagulation therapy in an atrial fibrillation population

Speaker: Ms G. Stynes (Uxbridge, GB)


Is major bleeding risk for oral anticoagulants similar between non-valvular atrial fibrillation patients newly initiated on warfarin and propensity-score matched NOAC initiators? A real world study

Speaker: Professor G. Lip (Liverpool, GB)


The HAS-BLED score for prediction of stroke and systemic embolism: insights from the PREvention oF thromboembolic events, European Registry in Atrial Fibrillation (PREFER in AF)

Speaker: Doctor M. Rohla (Bern, CH)


Anticoagulation management in patients with atrial fibrillation undergoing elective electrical cardioversion

Speaker: Doctor O. Erkuner (Maastricht, NL)


Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation

Speakers: Ms G. Stynes, Doctor E. Ueno, Ms G. Stynes, Professor G. Lip, Doctor M. Rohla...

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb